Investor Presentaiton

Q3 2021: A Record Quarter in the Slowest Season of the Year . $26.7M U.S. Net Revenue ○ +58% U.S. Year-over-Year growth ○ +5% U.S. Quarter-over-Quarter growth ~$8 Million Operating Cash Burn Q3 U.S. Net Revenue (in millions) $16.9M . $107.8 Million Quarter-End Cash $13.2M • On Track for European Launch in Early 2022, a $470 Million Market¹ +28% 1. Estimated total botulinum toxin market value for Europe in 2022; Clarivate Aesthetic Injectables Market Insights (November 2020) $26.7M +58% 2019 2020 2021 8 в 18

View entire presentation